Health Care·Pharmaceuticals·$277.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.83 | N/A | +9.06% |
management commentary, guidance changes, and full analysis available with Pro.
| +9.06% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the earnings performance, particularly the EPS. They emphasized their commitment to innovation and patient care.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering innovative solutions to patients.
This earnings report shows that Novartis was able to exceed EPS expectations, indicating strong operational performance. However, without revenue figures or guidance, investors may be cautious about the stock's future direction. The lack of stock reaction data suggests uncertainty in the market's response.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CHARLES SCHWAB CORP
Jul 18, 2023